rosiglitazone has been researched along with Axonal Injury, Diffuse in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, T; Song, J; Wei, X; Zhang, M; Zhao, J; Zhao, Y; Zhou, Y | 1 |
| Huang, T; Qin, J; Song, J; Wei, X; Zhang, M; Zhao, Y | 1 |
2 other study(ies) available for rosiglitazone and Axonal Injury, Diffuse
| Article | Year |
|---|---|
Hyperglycemia Aggravates Blood-Brain Barrier Disruption Following Diffuse Axonal Injury by Increasing the Levels of Inflammatory Mediators through the PPARγ/Caveolin-1/TLR4 Pathway.
Topics: Animals; Blood-Brain Barrier; Caveolin 1; Diffuse Axonal Injury; Endothelial Cells; Glucose; Humans; Hyperglycemia; Inflammation Mediators; Interleukin-6; Oxygen; PPAR gamma; Rats; Rosiglitazone; Tight Junction Proteins; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2023 |
Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Protects Blood-Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway.
Topics: Animals; Blood-Brain Barrier; Caveolin 1; Cells, Cultured; Diffuse Axonal Injury; Disease Models, Animal; Endothelial Cells; Glucose; Humans; Inflammation Mediators; PPAR gamma; Rats; Rosiglitazone; Tight Junction Proteins | 2019 |